DBV TECHNOLOGIES News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07.03.18	DBV Technologies to Present at the Barclays Global Healthcare Conference (GlobeNewswire)
26.02.18	DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients (GlobeNewswire)
26.02.18	DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients (GlobeNewswire)
20.02.18	DBV Technologies Reports December 31, 2017 Cash Position (GlobeNewswire)
14.02.18	DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut (GlobeNewswire)
12.02.18	DBV Technologies présente de nouveaux résultats lors du Congrès Annuel 2018 de l'AAAAI/WAO concernant sa plateforme Viaskin (GlobeNewswire)
01.02.18	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
16.01.18	Half-Year Report on DBV Technologies Liquidity Contract with Natixis (GlobeNewswire)
03.01.18	DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
04.12.17	DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE (Food Allergy Research & E... (GlobeNewswire)
28.11.17	DBV Technologies to Attend Citi's 2017 Global Healthcare Conference (GlobeNewswire)
14.11.17	DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association (GlobeNewswire)
31.10.17	DBV Technologies Reports September 30, 2017 Cash Position (GlobeNewswire)
20.10.17	DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age (GlobeNewswire)
12.10.17	DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut (GlobeNewswire)
01.09.17	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
29.08.17	DBV Technologies Announces Completion of Enrollment in Phase III Extension Study of Viaskin Peanut (GlobeNewswire)
02.08.17	DBV Technologies Initiates Phase III Study of Viaskin Peanut in Peanut-Allergic Patients One to Three Years of Age (GlobeNewswire)
28.07.17	DBV Technologies Reports First Half 2017 Financial Results (GlobeNewswire)
17.11.16	DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis (GlobeNewswire)
17.11.16	DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis (Businesswire)
12.11.16	DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting (GlobeNewswire)
12.11.16	DBV Technologies Announces Poster Presentations at the 2016 American College of Allergy, Asthma, and Immunology Meeting (Businesswire)
10.11.16	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
08.11.16	DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients (GlobeNewswire)
08.11.16	DBV Technologies Completes Enrollment of Phase II Study of Viaskin Milk for the Treatment of Milk Allergic Patients (Businesswire)
03.11.16	DBV Technologies Reports September 30, 2016 Cash Position (GlobeNewswire)
03.11.16	DBV Technologies Reports September 30, 2016 Cash Position (Businesswire)
26.10.16	DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology (GlobeNewswire)
26.10.16	DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy and Clinical Immunology (Businesswire)
24.10.16	DBV Technologies: Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut (GlobeNewswire)
24.10.16	Topline Results from Two-Year Follow-Up Study of Viaskin Peanut Show Long-Lasting and High Levels of Desensitization to Peanut (Businesswire)
21.09.16	DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow's Milk Protein Allergy (GlobeNewswire)
21.09.16	DBV Technologies Receives FDA Fast Track Designation for Viaskin Milk for the Treatment of Cow’s Milk Protein Allergy (Businesswire)
06.09.16	DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination (GlobeNewswire)
01.09.16	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
01.08.16	DBV Technologies Announces Expansion of Clinical Program of Viaskin Peanut for the Treatment of Peanut Allergy (GlobeNewswire)
05.07.16	DBV Technologies Proudly Welcomes Dr. Lucia Septién as Chief Medical Officer (GlobeNewswire)
27.06.16	DBV Technologies Announces Completion of Recruitment in Global Phase III Study of Viaskin Peanut for the Treatment of Peanut Allergic Children (GlobeNewswire)
21.06.16	DBV Technologies Announced Results of its 2016 Annual Meeting of Shareholders (GlobeNewswire)
21.06.16	DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Maïlys Ferrere (GlobeNewswire)
16.06.16	DBV Technologies to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
15.06.16	DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin® Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression (GlobeNewswire)
13.06.16	DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT® Provides Sustained Protection Against Anaphylaxis (GlobeNewswire)
07.06.16	DBV Technologies Announces Appointment of Leading Japanese Allergist, Dr. Motohiro Ebisawa, to its Scientific Advisory Board (GlobeNewswire)
01.06.16	DBV Technologies Data at EAACI 2016 Highlight Its Expansive Product Development in Food Allergies (GlobeNewswire)
31.05.16	DBV Technologies and Nestlé Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy (GlobeNewswire)
30.05.16	DBV Technologies: Mixed General Assembly of June 21, 2016 Procedures for obtaining preparatory documents for the Assembly (GlobeNewswire)
20.05.16	DBV Technologies to Attend Upcoming Investor Conferences (GlobeNewswire)
29.04.16	DBV Technologies Reports March 31, 2016 Cash Position (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	74.30	1.53 %	K V
Holcim	87.38	1.49 %	K V
Roche Hldg G	251.00	1.46 %	K V
Swiss Re	130.35	1.44 %	K V
UBS Group	27.07	1.35 %	K V
Swisscom	501.00	0.52 %	K V
Lonza Grp	532.40	0.26 %	K V
Nestle	74.08	0.14 %	K V
Sonova Hldg	295.60	0.00 %	K V
Geberit	512.20	-0.39 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu DBV TECHNOLOGIES

Aktien Top/Flop

Meistgelesene Nachrichten